Alterity Therapeutics Announces Director Departure
Alterity Therapeutics announced the departure of Geoffrey Kempler as a director effective November 21, 2025. Kempler's exit, given his significant holdings, may impact the company's strategic direction and investor confidence. Alterity focuses on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. The company's current market cap is A$97.88M, with a strong sell technical sentiment signal.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
Alterity Therapeutics Limited has announced that Geoffrey Kempler has ceased to be a director as of November 21, 2025. The announcement details Kempler’s interests in securities, which include fully paid ordinary shares and unlisted options. This change in directorship may influence the company’s strategic direction and investor confidence, given Kempler’s significant holdings and involvement in the company.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapeutic solutions for neurodegenerative diseases. The company is known for its innovative approaches in targeting conditions such as Alzheimer’s and Parkinson’s diseases.
Average Trading Volume: 14,994,693
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
See more data about ATH stock on TipRanks’ Stock Analysis page.
